ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Free Cash Flow Yield on January 14, 2025: -2.68%

ABL Bio Inc. Free Cash Flow Yield is -2.68% on January 14, 2025, a 16.27% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

ABL Bio Inc. 52-week high Free Cash Flow Yield is -1.80% on October 14, 2024, which is 32.65% above the current Free Cash Flow Yield.
ABL Bio Inc. 52-week low Free Cash Flow Yield is -3.69% on February 08, 2024, which is -37.65% below the current Free Cash Flow Yield.
ABL Bio Inc. average Free Cash Flow Yield for the last 52 weeks is -2.80%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years